Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-GD-59 in Graves' Disease
NCT02973802Phase 1Completed
- Sponsor
- Apitope
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ATX-GD-59 in Graves' disease, sponsored by Apitope. Primary endpoint: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities at 22 weeks. Started Sep 2016; status: completed.
02
Drugs
ATX-GD-59
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT02973802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973802.